Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02252042

Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)

Head and Neck Squamous Cell Cancer Clinical Trial

Official title:
A Phase III Randomized Trial of MK-3475 (Pembrolizumab) Versus Standard Treatment in Subjects With Recurrent or Metastatic Head and Neck Cancer

Clinical Trial Summary

This is a study of pembrolizumab (MK-3475, KEYTRUDA®) versus standard treatment (methotrexate, docetaxel or cetuximab) for the treatment of recurrent or metastatic head and neck squamous cell cancer (HNSCC). Participants will be randomly assigned to receive either pembrolizumab or Investigator's choice of standard treatment. The primary study hypothesis is that pembrolizumab treatment prolongs Overall Survival (OS) when compared to standard treatment.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02252042
Study type Interventional
Source Merck Sharp & Dohme LLC
Contact
Status Completed
Phase Phase 3
Start date November 17, 2014
Completion date August 15, 2022
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03667482 - Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer Phase 1
Completed NCT02083692 - Pilot Study of Metformin in Head and Neck Squamous Cell Cancer and Its Effects on Stromal-epithelial Metabolic Uncoupling Early Phase 1
Completed NCT02282371 - Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC) Phase 1
Active, not recruiting NCT03138070 - A Window of Opportunity Study to Assess the Modulation of Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC) By Preoperative Treatment With BYL719 N/A
Active, not recruiting NCT02159508 - Intensive Nutrition Counselling in Patients With Head and Neck Cancer N/A
Terminated NCT01790516 - Use of Pharmacogenetics to Select Erbitux or Cisplatin to Treat Head and Neck Cancer N/A
Completed NCT00574977 - Safety Study of Modified Vaccinia Virus to Cancer Phase 1
Completed NCT00592371 - Head and Neck Cancer Screening and Serum Repository N/A
Recruiting NCT02485548 - Cisplatin Plus Raltitrexed or 5-fluorouracil Concurrent With Radiotherapy for Head and Neck Squamous Cell Cancer Phase 3
Terminated NCT01326923 - Induction Chemo Then Concurrent Chemoradiotherapy With Cetuximab in Locally Advanced Head and Neck Squamous Cell Cancer Phase 2
Not yet recruiting NCT03975270 - Sintilimab in Combination With Nab-paclitaxel in Patients With HNSCC (Head and Neck Squamous Cell Carcinoma ) Phase 2
Terminated NCT04187872 - LITT and Pembrolizumab in Recurrent Brain Metastasis Phase 1
Recruiting NCT02327468 - Inovio TRT-001: Telomerase DNA Immunotherapy in Breast, Lung, and Pancreatic Cancers Phase 1
Active, not recruiting NCT01351103 - A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands Phase 1
Terminated NCT00260598 - LIFE-Lung Bronchoscopy in Patients at Risk for Developing Lung Cancer Phase 2
Completed NCT02163057 - Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma Phase 1/Phase 2
Recruiting NCT04856631 - A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer Phase 1/Phase 2